All In Biotech

Drug Trial Radar · NCT04401982

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Using Erythrocyte Mediated Angiography In Vivo

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jul 2, 2026

Primary completion

Mar 17, 2027

Study completion Mar 17, 2027

Sponsor

Lead sponsor
University of Maryland, BaltimoreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alcon Research
First posted
May 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and laser speckle contrast imaging (LSCI). The main questions this study aims to answer are: * Does Rocklatan produce greater increases in episcleral venous blood flow than latanoprost alone? * Can EMA and LSCI reliably detect changes in episcleral venous blood flow following treatment with these medications? Participants will: * Be randomized to receive either latanoprost or Rocklatan * Undergo imaging of the episcleral veins using EMA and LSCI before, during, and after treatment, and * Complete study visits that include standard ophthalmic examinations and intraocular pressure measurements. Hypothesis: The investigators hypothesize that latanoprost, which primarily increases uveoscleral outflow, will not significantly affect the distal episcleral circulation. In contrast, Rocklatan, through its netarsudil component, is expected to produce measurable increases in episcleral venous flow.

Conditions

  • Ocular Hypertension
  • Suspect Glaucoma

Interventions

  • Rocklatan (Netarsudil 0.02%/ latanoprost 0.005)Drug

    Rocklatan (Netarsudil 0.02%/ latanoprost 0.005) one drop nightly for 14-28 days, if randomized to Rocklatan after 28-35 days on Latanoprost.

  • Latanoprost (0.005%)Drug

    Latanoprost 0.005% one drop nightly for 28-35 days, then 14-28 days if randomized to continue on latanoprost.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Episcleral Venous Blood Flow Measured by Erythrocyte-Mediated Angiography (EMA)Time frame: Baseline (T0), 28-35 days from baseline (T1), 14-28 days from T1 (T2)
  2. Change in Retinal Arteriolar and Venular Blood Flow Measured by Erythrocyte-Mediated Angiography (EMA)Time frame: Baseline (T0), 28-35 days from baseline (T1), 14-28 days from T1 (T2)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Maryland Medical Center

    Baltimore, Maryland · Recruiting

  • University Physicians Inc.

    Baltimore, Maryland · Recruiting

  • UM Faculty Physicians, Inc. | 5900 Waterloo Crossing

    Columbia, Maryland · Recruiting

  • Maryland Eye Consultants and Surgeons

    Silver Spring, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.